دورية أكاديمية
Neisserial PorB immune enhancing activity and use as a vaccine adjuvant.
| العنوان: | Neisserial PorB immune enhancing activity and use as a vaccine adjuvant. |
|---|---|
| المؤلفون: | Yuen R; Department of Microbiology, Boston University School of Medicine, Boston, MA, USA., Kuniholm J; Department of Microbiology, Boston University School of Medicine, Boston, MA, USA., Lisk C; Section of Infectious Diseases, Department of Medicine, Boston Medical Center, Boston, MA, USA., Wetzler LM; Department of Microbiology, Boston University School of Medicine, Boston, MA, USA.; Section of Infectious Diseases, Department of Medicine, Boston Medical Center, Boston, MA, USA. |
| المصدر: | Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2019; Vol. 15 (11), pp. 2778-2781. Date of Electronic Publication: 2019 May 31. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2015- : Philadelphia, PA : Taylor & Francis Original Publication: Austin, Tex. : Landes Bioscience |
| مواضيع طبية MeSH: | Adjuvants, Immunologic*, Antigen-Presenting Cells/*immunology , Meningococcal Infections/*prevention & control , Porins/*immunology, Animals ; Animals, Genetically Modified ; Antibodies, Bacterial/blood ; Cytokines/immunology ; Female ; Immunoglobulin G/blood ; Mice ; Myeloid Differentiation Factor 88 ; Neisseria meningitidis ; Porins/administration & dosage ; T-Lymphocytes/immunology |
| مستخلص: | Our laboratory has focused on Porin B (PorB), an outer membrane protein from Neisseria meningitidis and TLR2 ligand-based adjuvant, to characterize specific molecular and cellular pathways involved in improved immune responses induced by vaccine adjuvants. PorB's ability to form micellar nanoparticular multi-molecular organized structures and its interaction with Toll-like receptor 2/1 complexes likely accounts for its potent adjuvant activity. Downstream from this stimulation, we have observed enhanced antigen uptake in antigen presenting cells (APC), greater antigen deposition in secondary lymphoid organs, and promotion of germinal center reactions. In mice, antigen-specific IgGs were increased after PorB adjuvanted vaccination using the model antigen ovalbumin (OVA). Likewise, this formulation resulted in more IL-4 and IFN-γ positive T cells. Mice that received PorB adjuvanted vaccinations benefitted from lower bacterial burdens when challenged with recombinant Listeria monocytogenes expressing OVA. Mouse models lacking MyD88 signaling in various APC types helped identify macrophages as an essential cell type for the adjuvant activity of PorB. We believe the work presented here provides examples of the mechanistic studies required to understand how vaccine adjuvants are contributing to the establishment of protective immunity. |
| References: | Vaccines (Basel). 2015 Apr 16;3(2):320-43. (PMID: 26343190) Eur J Immunol. 2007 Aug;37(8):2205-13. (PMID: 17621369) Protein Expr Purif. 2005 Dec;44(2):136-46. (PMID: 16027004) J Immunol. 2002 Feb 15;168(4):1533-7. (PMID: 11823477) J Immunol. 2006 Feb 15;176(4):2373-80. (PMID: 16455995) Biochim Biophys Acta. 2002 Feb 13;1589(1):1-13. (PMID: 11909637) Front Immunol. 2017 Mar 03;8:225. (PMID: 28316602) Annu Rev Immunol. 2002;20:197-216. (PMID: 11861602) Nature. 2014 Mar 27;507(7493):519-22. (PMID: 24531764) Nat Rev Immunol. 2009 Apr;9(4):287-93. (PMID: 19247370) Immunity. 2008 Aug 15;29(2):272-82. (PMID: 18656388) Nat Med. 2013 Dec;19(12):1597-608. (PMID: 24309663) Vaccine. 2011 Mar 16;29(13):2461-73. (PMID: 21256188) J Immunol. 2004 May 15;172(10):6065-73. (PMID: 15128790) Sci Rep. 2017 Apr 7;7(1):736. (PMID: 28389664) Nat Biotechnol. 2015 Jan;33(1):64-72. (PMID: 25485616) PLoS One. 2013 Dec 11;8(12):e82171. (PMID: 24349212) J Immunol. 2005 Mar 15;174(6):3545-50. (PMID: 15749891) Front Immunol. 2013 May 16;4:114. (PMID: 23720661) PLoS One. 2013 Jun 19;8(6):e66312. (PMID: 23840439) Vaccine. 2018 Nov 29;36(50):7689-7699. (PMID: 30381152) Expert Rev Vaccines. 2011 Apr;10(4):499-511. (PMID: 21506647) Vaccine. 2012 Jun 19;30(29):4341-8. (PMID: 22682289) Immunol Res. 2009;45(1):25-36. (PMID: 19597998) |
| معلومات مُعتمدة: | R01 AI040944 United States AI NIAID NIH HHS |
| فهرسة مساهمة: | Keywords: Adjuvant; MyD88; Neisseria meningitidis; PorB; TLR; germinal center |
| المشرفين على المادة: | 0 (Adjuvants, Immunologic) 0 (Antibodies, Bacterial) 0 (Cytokines) 0 (Immunoglobulin G) 0 (Myd88 protein, mouse) 0 (Myeloid Differentiation Factor 88) 0 (Porins) 0 (porin protein, Neisseria) |
| تواريخ الأحداث: | Date Created: 20190522 Date Completed: 20200506 Latest Revision: 20201213 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC6930065 |
| DOI: | 10.1080/21645515.2019.1609852 |
| PMID: | 31112447 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 2164-554X |
|---|---|
| DOI: | 10.1080/21645515.2019.1609852 |